Market Watch – by Joseph Adinolfi
Two U.S. citizens who contracted the ebola virus in Liberia have showed signs of recovery after receiving an experimental treatment called ZMapp, which was developed by Mapp Biopharmaceutical Inc., according to CNN.
The medicine is a “three-mouse monoclonal antibody,” which means that antibodies were harvested from mice exposed to the virus, CNN reported. These antibodies in turn can boost the human immune system’s ability to fight off the virus. Continue reading “Experimental drug improves ebola patients’ condition”